GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » EV-to-EBITDA

BetterLife Pharma (XCNQ:BETR) EV-to-EBITDA : -5.50 (As of May. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BetterLife Pharma's enterprise value is C$15.17 Mil. BetterLife Pharma's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 was C$-2.76 Mil. Therefore, BetterLife Pharma's EV-to-EBITDA for today is -5.50.

The historical rank and industry rank for BetterLife Pharma's EV-to-EBITDA or its related term are showing as below:

XCNQ:BETR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -585.87   Med: 0   Max: 0.08
Current: -5.5

During the past 13 years, the highest EV-to-EBITDA of BetterLife Pharma was 0.08. The lowest was -585.87. And the median was 0.00.

XCNQ:BETR's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs XCNQ:BETR: -5.50

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), BetterLife Pharma's stock price is C$0.125. BetterLife Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was C$-0.022. Therefore, BetterLife Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


BetterLife Pharma EV-to-EBITDA Historical Data

The historical data trend for BetterLife Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma EV-to-EBITDA Chart

BetterLife Pharma Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.77 -1.42 -1.96 -1.57 -1.93

BetterLife Pharma Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.52 -1.93 -1.74 -1.58 -3.78

Competitive Comparison of BetterLife Pharma's EV-to-EBITDA

For the Biotechnology subindustry, BetterLife Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's EV-to-EBITDA falls into.



BetterLife Pharma EV-to-EBITDA Calculation

BetterLife Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=15.173/-2.759
=-5.50

BetterLife Pharma's current Enterprise Value is C$15.17 Mil.
BetterLife Pharma's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BetterLife Pharma  (XCNQ:BETR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BetterLife Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.125/-0.022
=At Loss

BetterLife Pharma's share price for today is C$0.125.
BetterLife Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.022.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


BetterLife Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma (XCNQ:BETR) Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Ahmad Doroudian Director, Senior Officer